Market Access
Biotech's next growth cycle: Renewed confidence comes with c...
Renewed confidence across biopharma is welcome and long overdue after a prolonged period of constraint. But confidence alone is not enough.
Oncology
The future of oncology is adaptive: What ESMO 2026 revealed ...
Across tumours, three developments repeatedly surfaced throughout the congress, each reflecting a notable transition in how cancer is being managed.
Market Access
Sponsored
Solution Spotlight: Acumetis Model Builder
Acumetis Model Builder is a web-based platform that generates complete, formula-linked Excel cost-effectiveness and budget impact models in minutes.
Patients
Healthcare wants patients at the centre. So, why are they st...
Claire Gillis reflects on a surprising controversy at ESMO 2026, and the uncomfortable questions it raises for healthcare.
Digital
The growing use of synthetic data in modern pharma
The issue isn't whether synthetic data is useful. It is what question we are asking it to answer.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
